Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPC vs Chlorhexidine for VAP Prevention in ICU
NCT06966817Enrolling by invitation
- Sponsor
- Sağlık Bilimleri Üniversitesi
- Start
- May 2024
- Primary completion
- Jun 2025
- Modality
- Conventional Liposomes, Small Molecules
- Countries
- 1
01
Overview
Trial of cetylpyridinium chloride in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Sağlık Bilimleri Üniversitesi. Primary endpoints: Incidence of Ventilator-Associated Pneumonia at 5 days and Oral Health Assessment at 5 days. Started May 2024; status: enrolling by invitation.
02
Drugs
cetylpyridinium chloride
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT06966817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06966817.